Press releases

Press releases and press packs are intended to journalists, investors and shareholders. 

Paris, France and New York, NY  December 28, 2006

Canadian Federal Court of Appeals rules in sanofi-aventis’ favor in the Canadian Plavix Notice of Compliance proceedings

Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) announced today that the Canadian Federal Court of Appeals dismissed Apotex Inc.’s (“Apotex”) appeal of the judgment of the Federal Court of Canada prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex in connection with its 75mg clopidogrel bisulfate tablets. Absent a Notice of Compliance, Apotex cannot market its 75mg clopidogrel bisulfate tablets in Canada.

About sanofi-aventis

Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

• Download the press release dated December 28, 2006 (new window, PDF, 0.4 MB)